- Home
- PMEC vs GRML Comparison
PMEC vs GRML Comparison
Compare PMEC & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PMEC | GRML |
|---|---|---|
| Founded | 1984 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 5 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 34.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PMEC | GRML |
|---|---|---|
| Price | $0.55 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 151.0K | ★ 3.7M |
| Earning Date | 07-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.18 |
| 52 Week High | $2.44 | $0.55 |
Technical Indicators
Market Signals| Indicator | PMEC | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 29.30 |
| Support Level | $0.52 | N/A |
| Resistance Level | $0.80 | $0.34 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 22.90 | 11.56 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.